Related Experiment Videos
Kawasaki disease: an update
1Division of Pediatric Cardiology, St. Louis University School of Medicine, MO, USA.
Insights
Kawasaki disease is a primary cause of acquired heart disease in children, leading to potential long-term cardiac issues. Early treatment with immunoglobulin and aspirin is crucial for managing this vasculitis and preventing coronary artery complications.
Area of Science:
- Pediatrics
- Cardiology
- Immunology
Background:
- Kawasaki disease is the leading cause of acquired heart disease in children globally.
- It is an acute systemic vasculitis of unknown origin, primarily affecting those under five.
- Diagnosis relies on clinical manifestations and excluding other conditions.
Purpose of the Study:
- To summarize the key aspects of Kawasaki disease, including its etiology, diagnosis, and management.
- To highlight the cardiovascular implications and long-term risks associated with the condition.
Main Methods:
- Clinical diagnosis based on characteristic symptoms and differential diagnosis.
- Review of established treatment protocols for acute Kawasaki disease.
- Discussion of long-term management strategies for affected individuals.
Main Results:
- Coronary artery abnormalities occur in 30-35% of untreated cases.
- Myocardial infarction and mortality are seen in up to 2% of untreated cases.
- Intravenous immunoglobulin and aspirin are standard acute treatments.
Conclusions:
- Prompt treatment is vital to mitigate cardiovascular damage in Kawasaki disease.
- Children with coronary involvement require ongoing cardiac risk assessment and management.
- Kawasaki disease contributes to the increasing prevalence of adult ischemic heart disease.
Abstract:
Kawasaki disease is the leading cause of acquired heart disease in children in many parts of the world. It is an acute systemic vasculitis of unknown etiology predominantly affecting children under 5 years of age. It is diagnosed clinically by the presence of a constellation of manifestations and exclusion of other diseases with similar findings. Children develop a spectrum of cardiovascular manifestations including coronary artery involvement in 30-35% of untreated cases with myocardial infarction and death in < or = 2% of them. Acute stage treatment is by administration of intravenous immunoglobulin and aspirin. Those with coronary artery involvement need long-term cardiac risk stratification and management because many of them will become the part of a growing pool of adults with ischemic heart disease.